The paper demonstrates that mRNA-delivered human IgA can protect mucosal tissues from bacterial infection by trafficking to mucosal sites and limiting bacterial invasion.

bioRxiv · Jan 3, 2023 · PreprintImmunology

A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge

A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss

This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.

bioRxiv · Dec 17, 2022 · PreprintImmunology

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection

B. A. Bollman, N. Nunna, K. Bahl, C. J. Hsiao, H. Bennett, S. Butler, B. Foreman, K. E. Burgomaster, M. Aleshnick, W.-P. Kong, B. E. Fisher, T. J. Ruckward, K. M. Morabito, B. S. Graham, K. A. Dowd, , A. Carfi

This study compares two ZIKV mRNA vaccines, showing that mRNA-1893 provides complete protection at a lower dose than mRNA-1325 in non-human primates.

bioRxiv · Oct 11, 2022 · PreprintImmunology

Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains

G. Stewart-Jones, S. M. Elbashir, K. Wu, D. Lee, I. Renzi, B. Ying, M. Koch, C. E. Sein, A. Choi, B. Whitener, D. Garcia-Dominguez, C. Henry, A. Woods, L. Ma, D. Montes Berrueta, , A. Carfi

The paper develops and evaluates an mRNA vaccine, mRNA-1283, encoding SARS-CoV-2 spike N-terminal and receptor-binding domains, showing improved immunogenicity and protection against multiple variants in mice.

bioRxiv · Oct 7, 2022 · PreprintImmunology

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

S. M. Scheaffer, D. Lee, B. Whitener, B. Ying, K. Wu, H. Jani, P. Martin, N. J. Amato, L. E. Avena, D. M. Berrueta, S. D. Schmidt, S. O'Dell, A. Nasir, G.-Y. Chuang, G. Stewart-Jones, , M. S. Diamond

This study evaluates bivalent SARS-CoV-2 mRNA vaccines and finds they induce broader neutralizing antibodies and better protection against BA.5 Omicron compared to monovalent vaccines.

bioRxiv · Sep 12, 2022 · PreprintMicrobiology

Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in mice

B. Ying, S. M. Scheaffer, B. Whitener, C.-Y. Liang, O. Dmytrenko, S. Mackin, K. Wu, D. Lee, L. E. Avena, Z. Chong, J. B. Case, L. Ma, T. Kim, C. Sein, A. Woods, , M. S. Diamond

This study shows that boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibodies and protection against B.1.1.529 in mice, with the Omicron-matched booster showing slightly better outcomes.

bioRxiv · Feb 7, 2022 · PreprintMicrobiology

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

bioRxiv · Oct 23, 2021 · PreprintImmunology

Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains

B. Ying, B. Whitener, L. A. VanBlargan, A. O. Hassan, S. Shrihari, C.-Y. Liang, C. E. Karl, S. Mackin, R. E. Chen, N. M. Kafai, S. H. Wilks, D. J. Smith, J. M. Carreno, G. Singh, F. Krammer, , M. S. Diamond

This study evaluates the protective efficacy of mRNA vaccines against SARS-CoV-2 variants in mice, showing that low-dose vaccines lead to breakthrough infections with Delta variant.

bioRxiv · Aug 25, 2021Microbiology

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants

A. Choi, M. Koch, K. Wu, G. Dixon, J. Oestreicher, H. Legault, G. B. E. Stewart-Jones, T. Colpitts, R. Pajon, H. Bennett, A. Carfi, D. K. Edwards

This study evaluates the neutralizing activity of mRNA-1273 vaccine-induced sera against SARS-CoV-2 variants, finding reduced but still effective neutralization against several variants compared to the wild-type virus.

bioRxiv · Jun 28, 2021Microbiology

Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

K. S. Corbett, A. Werner, S. O'Connell, M. Gagne, L. Lai, J. Moliva, B. Flynn, A. Choi, M. Koch, K. E. Foulds, S. Andrew, D. Flebbe, E. Lamb, S. T. Nurmukhambetova, S. Provost, , M. Suthar

This study evaluates mRNA-1273 vaccine efficacy against SARS-CoV-2 B.1.351 in nonhuman primates, finding that two doses significantly reduce viral replication in the airways.

bioRxiv · May 21, 2021 · PreprintImmunology

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

K. Wu, A. Choi, M. Koch, S. Elbashir, L. Ma, D. Lee, A. Woods, C. Henry, C. Palandjian, A. Hill, H. Jani, J. Quinones, N. Nunna, S. O'Connell, A. B. McDermott, , D. K. Edwards

This study evaluates updated SARS-CoV-2 mRNA vaccines in mice, showing that mRNA-1273.351 boosts neutralization against B.1.351 and mRNA-1273.211 provides broad cross-variant protection.

bioRxiv · Apr 13, 2021Microbiology

SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques

C. G. Garrado, A. D. Curtis, M. Dennis, S. H. Pathak, H. Gao, D. Montefiori, M. Tomai, C. B. Fox, P. A. Kozlowski, T. Scobey, J. E. Munt, M. L. Mallory, P. T. Saha, M. G. Hudgens, L. C. Lindesmith, , S. R. Permar

This study evaluates two SARS-CoV-2 vaccines in infant rhesus macaques, finding both induce durable antibody and T cell responses without adverse effects.

bioRxiv · Apr 5, 2021Immunology

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

M. Meyer, Y. Wang, D. Edwards, G. R. Smith, A. B. Rubenstein, P. Ramanathan, C. E. Mire, C. Pietzsch, X. Chen, Y. Ge, W. S. Cheng, C. Henry, A. Woods, L. Ma, G. B. E. Stewart-Jones, , A. Bukreyev

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

bioRxiv · Jan 25, 2021 · PreprintImmunology

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

K. Wu, A. P. Werner, J. I. Moliva, M. Koch, A. Choi, G. B. E. Stewart-Jones, H. Bennett, S. Boyoglu-Barnum, W. Shi, B. S. Graham, A. Carfi, K. S. Corbett, R. A. Seder, D. K. Edwards

This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.

bioRxiv · Jan 25, 2021 · PreprintImmunology

The N-terminus of varicella-zoster virus glycoprotein B has a functional role in fusion.

S. L. Oliver, Y. Xing, D.-H. Chen, S. H. Roh, G. D. Pintilie, D. A. Bushnell, M. H. Sommer, E. Yang, A. Carfi, W. Chiu, A. M. Arvin

This study identifies the N-terminus of VZV glycoprotein B as critical for membrane fusion, showing that mutations in this region impair viral propagation.

bioRxiv · Sep 8, 2020Microbiology